☆ 4.8 Letter

Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence

JOURNAL OF HEPATOLOGY (2017)

期刊

JOURNAL OF HEPATOLOGY

卷 67, 期 6, 页码 1355-1356

出版社

ELSEVIER SCIENCE BV

DOI: 10.1016/j.jhep.2017.07.026

关键词

-

类别

Gastroenterology & Hepatology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Gastroenterology & Hepatology

Therapeutic strategies for post-transplant recurrence of hepatocellular carcinoma

Carlo Sposito, Davide Citterio, Matteo Virdis, Carlo Battiston, Michele Droz Dit Busset, Maria Flores, Vincenzo Mazzaferro

Summary: Despite strict selection criteria, up to 20% of patients experience hepatocellular carcinoma recurrence after liver transplantation. There are no established adjuvant treatments to prevent recurrence, however, a balanced use of immunosuppression is advised. Pre- and post-transplant predictors of recurrence can help determine the frequency and duration of follow-up. Survival after recurrence is poor, with timing being a key factor. Treatment options depend on the timing and presentation of the disease. Surgical treatment provides a survival benefit, especially in late recurrence, while the effectiveness of locoregional treatments is still uncertain. Sorafenib is proven to be safe and effective, while data for other drugs are limited.

WORLD JOURNAL OF GASTROENTEROLOGY (2022)

添加到收藏夹

Article Immunology

Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan

Chen-Ta Chi, Chi-Yi Chen, Chien-Wei Su, Po-Yueh Chen, Chi-Jen Chu, Keng-Hsin Lan, I-Cheng Lee, Ming-Chih Hou, Yi-Hsiang Huang

Summary: The study examines the impact of DAAs treatment on HCC patients with CHC in Taiwan, showing high SVR rates within BCLC B HCV-HCC patients and no increased risk of HCC recurrence or progression. For intermediate stage HCC patients, DAAs treatment results in a high percentage maintaining in BCLC B status.

JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Post-transplant inflammatory cytokine signature adds value for predicting tumor recurrence after liver transplantation for hepatocellular carcinoma

Kevin Tak-Pan Ng, Jiang Liu, Oscar Wai-Ho Yeung, Li Pang, Hoi Chung Shiu, Hui Liu, Xin Xiang Yang, Albert Chi-Yan Chan, Tiffany Cho-Lam Wong, Chung Mau Lo, Kwan Man

Summary: This study found that post-transplant cytokines CCL11, IFN alpha 2, and IL17A are significant predictors of tumor recurrence and survival after liver transplantation for hepatocellular carcinoma. A prediction model including these cytokines, the UCSF criteria, and pre-transplant AFP accurately predicted post-transplant tumor recurrence and guided refinements in surveillance and therapeutic strategies.

HEPATOLOGY INTERNATIONAL (2023)

添加到收藏夹

Article Oncology

Methylation site APC112043544 as a potential biomarker for post-transplant hepatocellular carcinoma recurrence

Zhentao Yang, Wei Chen, Hai Zhu, Liang Zhang, Ke Zhou, Hong Tang, Ruiqi Sun, Yiqian Huang, Haiyang Xie, Shusen Zheng, Changku Jia

Summary: This study found that the APC112043544 methylation site is an independent predictor for HCC recurrence after liver transplantation and may serve as a potential biomarker.

FUTURE ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Therapeutic Approach to Post-Transplant Recurrence of Hepatocellular Carcinoma: Certainties and Open Issues

Giuseppe Marrone, Maria Sandrina Leone, Marco Biolato, Antonio Liguori, Giuseppe Bianco, Gabriele Spoletini, Antonio Gasbarrini, Luca Miele, Maurizio Pompili

Summary: Hepatocellular carcinoma (HCC) is increasingly being treated with liver transplantation (LT). Successful treatment depends on selecting appropriate candidates and implementing various therapies before and after transplantation. The risk of recurrence and suitable treatment options vary among patients and transplant centers. The use of immunosuppressive therapy and potential drug interactions further complicate patient management. This paper reviews the current literature on post-transplant HCC recurrence, addressing evidence and controversies.

CANCERS (2023)

添加到收藏夹

Review Gastroenterology & Hepatology

The management of post-transplantation recurrence of hepatocellular carcinoma

Luckshi Rajendran, Tommy Ivanics, Marco P. A. W. Claasen, Hala Muaddi, Gonzalo Sapisochin

Summary: The annual incidence of hepatocellular carcinoma (HCC) is increasing, and liver transplantation is the preferred treatment. However, there is currently no consensus on post-transplantation cancer surveillance and recurrence management for HCC. Early tumor detection, re-evaluation of immunosuppression regimens, and staging are important for guiding decision-making and maximizing treatment effect. Treatment recommendations specific to recurrence type are provided.

CLINICAL AND MOLECULAR HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals

Yuki Tahata, Ryotaro Sakamori, Ryoko Yamada, Takahiro Kodama, Hayato Hikita, Hideki Hagiwara, Yasuharu Imai, Naoki Hiramatsu, Shinji Tamura, Keiji Yamamoto, Masahide Oshita, Kazuyoshi Ohkawa, Taizo Hijioka, Hiroyuki Fukui, Toshifumi Ito, Yoshinori Doi, Yukinori Yamada, Takayuki Yakushijin, Yuichi Yoshida, Tomohide Tatsumi, Tetsuo Takehara

Summary: A prediction model incorporating baseline BMI, FIB-4 index, albumin level, and alpha-foetoprotein level was developed to predict HCC occurrence after DAA-mediated SVR. The model showed high sensitivity and negative predictive value at 2 and 3 years post-SVR, providing an efficient surveillance strategy for HCC occurrence.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Article Chemistry, Analytical

Label-Free Follow-Up Surveying of Post-Treatment Efficacy and Recurrence in Nasopharyngeal Carcinoma Patients with Fiberoptic Raman Endoscopy

Chi Shu, Wei Zheng, Kan Lin, Chweeming Lim, Zhiwei Huang

Summary: This study applies fiberoptic Raman endoscopy to conduct follow-up surveys and accurate detection of tumor recurrence in post-treatment NPC patients. The Raman endoscopy shows significant spectral differences among normal tissue, NPC, and nonrecurring post-treatment patients, with high diagnostic accuracy for distinguishing recurrent NPC from post-treatment inflammation and fibrosis. This work demonstrates the clinical potential of fiberoptic Raman endoscopy as a powerful diagnostic tool for post-treatment surveying and recurrent tumor detection at the molecular level.

ANALYTICAL CHEMISTRY (2021)

添加到收藏夹

Article Oncology

Radiomics-guided prognostic assessment of early-stage hepatocellular carcinoma recurrence post-radical resection

Qu Xie, Zeyin Zhao, Yanzhen Yang, Dan Long, Cong Luo

Summary: This study aimed to construct models using radiomics derived from enhanced computed tomography (CT) imaging to predict the risk of postoperative recurrence in early-stage hepatocellular carcinoma patients. Clinical, radiomic, and combined models were built using four algorithms and evaluated through cross-validation. The results showed that the combined models outperformed those relying solely on clinical or radiomic features. This research provides clinicians with a valuable tool to predict postoperative recurrence and inform early preventive strategies.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Metabolomic biomarkers for the diagnosis and post-transplant outcomes of AFP negative hepatocellular carcinoma

Zuyuan Lin, Huigang Li, Chiyu He, Modan Yang, Hao Chen, Xinyu Yang, Jianyong Zhuo, Wei Shen, Zhihang Hu, Linhui Pan, Xuyong Wei, Di Lu, Shusen Zheng, Xiao Xu

Summary: This study identified three novel markers for the diagnosis of AFP negative HCC using metabolomic profiling. A three-marker diagnostic model and nomogram were established, which could serve as potential non-invasive tools for the diagnosis of AFP negative HCC. Additionally, the level of MG(18:2/0:0/0:0) showed good prognosis prediction performance for AFP negative HCC patients.

FRONTIERS IN ONCOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Early Versus Late Recurrence of Hepatocellular Carcinoma After Surgical Resection Based on Post-recurrence Survival: an International Multi-institutional Analysis

Tao Wei, Xu-Feng Zhang, Fabio Bagante, Francesca Ratti, Hugo P. Marques, Silvia Silva, Olivier Soubrane, Vincent Lam, George A. Poultsides, Irinel Popescu, Razvan Grigorie, Sorin Alexandrescu, Guillaume Martel, Aklile Workneh, Alfredo Guglielmi, Tom Hugh, Yi Lv, Luca Aldrighetti, Timothy M. Pawlik

Summary: The study found that setting the time point for recurrence at 8 months is beneficial for distinguishing early from late recurrence, with early recurrence patients typically having shorter survival time and post-recurrence survival, as well as less likely to receive curative treatment. Curative-intent retreatment for late recurrence patients is associated with similar overall survival compared to patients without recurrence.

JOURNAL OF GASTROINTESTINAL SURGERY (2021)

添加到收藏夹

Article Surgery

Reduced Rates of Post-Transplant Recurrent Hepatocellular Carcinoma in Non-Alcoholic Steatohepatitis: A Propensity Score Matched Analysis

Ryan Lamm, Peter J. Altshuler, Keyur Patel, Osama Shaheen, Angel Paulo Amante, Jesse Civan, Warren Maley, Adam Frank, Carlo Ramirez, Jaime Glorioso, Ashesh Shah, Hien Dang, Adam S. Bodzin

Summary: Non-alcoholic steatohepatitis (NASH)-related hepatocellular carcinoma (HCC) has become the second leading cause of HCC-related liver transplantation in the United States. The study found that NASH patients had a lower rate of post-transplant recurrence compared to non-NASH patients at 5 years, although the recurrence-free survival was similar.

TRANSPLANT INTERNATIONAL (2022)

添加到收藏夹

Article Surgery

Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma

Parissa Tabrizian, Matthew L. Holzner, Neil Mehta, Karim Halazun, Vatche G. Agopian, Francis Yao, Ronald W. Busuttil, John Roberts, Jean C. Emond, Benjamin Samstein, Robert S. Brown, Marc Najjar, William C. Chapman, Majella Mb Doyle, Sander S. Florman, Myron E. Schwartz, Josep M. Llovet

Summary: This study aimed to investigate the 10-year outcomes of patients with hepatocellular carcinoma (HCC) after liver transplant (LT), particularly those who were downstaged to meet the transplant criteria. The results showed that patients who successfully downstaged their disease had better overall survival rates, validating the effectiveness of downstaging and highlighting the importance of individualized decision-making when choosing surgical management for HCC recurrence after LT.

JAMA SURGERY (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Preoperative Radiomics Nomogram Based on CT Image Predicts Recurrence-Free Survival After Surgical Resection of Hepatocellular Carcinoma

Zeyong Li, Jialin Yu, Yehan Li, Ying Liu, Manjing Zhang, Hanfeng Yang, Yong Du

Summary: This study constructed preoperative models based on CT radiomics, radiologic and clinical features to predict recurrence-free survival (RFS) after liver resection (LR) of BCLC 0 to B stage hepatocellular carcinoma (HCC) and to classify the prognosis.

ACADEMIC RADIOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy

Junyi Shen, Weili Qi, Junlong Dai, Shusheng Leng, Kangyi Jiang, Yu Zhang, Shun Ran, Chuan Li, Tianfu Wen

Summary: This study compared the effects of tenofovir (TDF) and entecavir (ETV) on the recurrence of hepatocellular carcinoma (HCC) beyond the Milan criteria. The results showed that TDF treatment significantly reduced the risk of HCC recurrence compared to ETV therapy.

CHINESE MEDICAL JOURNAL (2022)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Hepatic splenosis mimicking hepatocellular carcinoma in metabolic associated fatty liver disease

Tommaso Pessarelli, Silvia Crespi, Barbara Antonelli, Marco Maggioni, Massimo Iavarone

DIGESTIVE AND LIVER DISEASE (2022)

添加到收藏夹

Article Oncology

Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation

Kyunghye Bang, Andrea Casadei-Gardini, Changhoon Yoo, Massimo Iavarone, Min-Hee Ryu, Sook Ryun Park, Hyung-Don Kim, Young-In Yoon, Dong-Hwan Jung, Gil-Chun Park, Chul-Soo Ahn, Deok-Bog Moon, Shin Hwang, Ki-Hun Kim, Gi-Won Song, Chiara Mazzarelli, Eleonora Alimenti, Stephen L. Chan, Massimo De Giorgio, Baek-Yeol Ryoo, Sung-Gyu Lee

Summary: This study investigated the efficacy and safety of lenvatinib in patients with post-liver transplantation (LT) hepatocellular carcinoma (HCC) recurrence. The results showed consistent efficacy and toxicity profiles of lenvatinib in these patients, comparable to previous studies on non-LT HCC patients. In addition, the baseline ALBI grade was associated with improved overall survival in post-LT lenvatinib-treated patients.

CANCER MEDICINE (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib

Victor Sapena, Massimo Iavarone, Loreto Boix, Floriana Facchetti, Maria Guarino, Marco Sanduzzi Zamparelli, Alessandro Granito, Esther Samper, Mario Scartozzi, Josep Corominas, Giorgia Marisi, Alba Diaz, Andrea Casadei-Gardini, Laura Gramantieri, Pietro Lampertico, Filomena Morisco, Ferran Torres, Jordi Bruix, Maria Reig

Summary: The risk of DAE development in HCC patients receiving TKIs may be related to the AGT2 (rs4762) gene variant.

WORLD JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Benign liver lesions 2022: Guideline for clinical practice of Associazione Italiana Studio del Fegato (AISF), Societa Italiana di Radiologia Medica e Interventistica (SIRM), Societa Italiana di Chirurgia (SIC), Societa Italiana di Ultrasonologia in Medicina e Biologia (SIUMB), Associazione Italiana di Chirurgia Epatobilio-Pancreatica (AICEP), Societa Italiana Trapianti d'Organo (SITO), Societa Italiana di Anatomia Patologica e Citologia Diagnostica (SIAPEC-IAP) - Part I - Cystic lesions

Maurizio Pompili, Francesco Ardito, Enrico Brunetti, Giuseppe Cabibbo, Fabrizio Calliada, Umberto Cillo, Ilario de Sio, Rita Golfieri, Mauro Grova, Salvatore Gruttadauria, Maria Guido, Massimo Iavarone, Tommaso Manciulli, Duilio Pagano, Irene Pettinari, Francesco Santopaolo, Maurizio Soresi, Agostino Colli

Summary: Benign liver lesions are increasingly diagnosed, and there is a need for updated guidelines for their management. This article presents the first part of a guideline on the characterization and clinical management of benign focal liver lesions based on Italian rules and methodologies.

DIGESTIVE AND LIVER DISEASE (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Benign liver lesions 2022: Guideline for clinical practice of Associazione Italiana Studio del Fegato (AISF)

Maurizio Pompili, Francesco Ardito, Enrico Brunetti, Giuseppe Cabibbo, Fabrizio Calliada, Umberto Cillo, Ilario de Sio, Rita Golfieri, Mauro Grova, Salvatore Gruttadauria, Maria Guido, Massimo Iavarone, Tommaso Manciulli, Duilio Pagano, Irene Pettinari, Francesco Santopaolo, Maurizio Soresi, Agostino Colli

Summary: Benign liver lesions, including hepatic cysts and solid benign tumors, have different prevalence, clinical relevance, symptoms, and natural history. Updated guidelines for their diagnosis and clinical management have been drafted, emphasizing evidence-based clinical, diagnostic, and therapeutic approaches. This article presents the second part of the guideline, focusing on the diagnosis and management of hemangioma, focal nodular hyperplasia, and hepatocellular adenoma.

DIGESTIVE AND LIVER DISEASE (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study

Massimo Iavarone, Giulia Tosetti, Floriana Facchetti, Matilde Topa, Joey Ming Er, Shou Kit Hang, Debora Licari, Andrea Lombardi, Roberta D'Ambrosio, Elisabetta Degasperi, Alessandro Loglio, Chiara Oggioni, Riccardo Perbellini, Riccardo Caccia, Alessandra Bandera, Andrea Gori, Ferruccio Ceriotti, Luigia Scudeller, Antonio Bertoletti, Pietro Lampertico

Summary: This study found that patients with cirrhosis have a suboptimal immune response to COVID-19 vaccines, particularly in those who have not been infected with SARS-CoV-2 before. However, the cellular immune response in patients with cirrhosis remains preserved, and a low rate of breakthrough infections was observed.

DIGESTIVE AND LIVER DISEASE (2023)

添加到收藏夹

Article Immunology

Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments

Francesco Tovoli, Dante Pio Pallotta, Vito Sansone, Massimo Iavarone, Massimo De Giorgio, Luca Ielasi, Giovan Giuseppe Di Costanzo, Paolo Giuffrida, Rodolfo Sacco, Tiziana Pressiani, Maria Francesca Di Donato, Franco Trevisani, Stefano Fagiuoli, Fabio Piscaglia, Alessandro Granito

Summary: This study retrospectively analyzed the characteristics and outcomes of sorafenib-treated HCC patients in a large multicenter dataset, showing that multimodal and sequential treatments are relatively frequent in post-LT HCC patients and contribute to a remarkable overall survival, together with favorable baseline characteristics.

TRANSPLANTATION (2023)

添加到收藏夹

Article Oncology

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Andrea Casadei-Gardini, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, Jose Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Margarida Montes, Caterina Vivaldi, Caterina Solda, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Mara Persano, Angelo Della Corte, Francesca Ratti, Francesco De Cobelli, Luca Aldrighetti, Stefano Cascinu, Alessandro Cucchetti

Summary: This retrospective multi-center study compared the clinical efficacy and safety of lenvatinib and atezolizumab plus bevacizumab as a first-line treatment for unresectable HCC. The results showed that atezolizumab plus bevacizumab did not have a significant survival advantage over lenvatinib overall. However, lenvatinib had a higher overall survival rate in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease, while atezolizumab plus bevacizumab had a higher overall survival rate in patients with viral hepatitis. After adjusting for population, atezolizumab plus bevacizumab provided better safety profile for most adverse events.

EUROPEAN JOURNAL OF CANCER (2023)

添加到收藏夹

Article Oncology

Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, Jose Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Takumi Kawaguchi, Margarida Montes, Caterina Vivaldi, Caterina Solda, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Antonella Cammarota, Valentina Burgio, Stefano Cascinu, Andrea Casadei-Gardini

Summary: This study compares the response rates of lenvatinib and atezolizumab plus bevacizumab in the first-line treatment of hepatocellular carcinoma (HCC) patients. The results show that lenvatinib achieves higher response rates in all patient subgroups. Patients who achieve complete response with atezolizumab plus bevacizumab can achieve a better overall survival compared to other treatments.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Low-Baseline PD1+Granulocytes Predict Responses to Atezolizumab-Bevacizumab in Hepatocellular Carcinoma

Catia Giovannini, Fabrizia Suzzi, Francesco Tovoli, Mariangela Bruccoleri, Mariarosaria Marseglia, Eleonora Alimenti, Francesca Fornari, Massimo Iavarone, Fabio Piscaglia, Laura Gramantieri

Summary: By using a simple cytofluorimetric test on peripheral blood, we discovered that patients with a low baseline PD1+ granulocyte percentage are more likely to benefit from atezolizumab-bevacizumab treatment. These findings need to be validated in larger cohorts to determine the potential use of this test in clinical practice.

CANCERS (2023)

添加到收藏夹

Meeting Abstract Gastroenterology & Hepatology

USEFULNESS OF LONGITUDINAL ASSESSMENT OF AFP IN DAA CURED HCV CIRRHOTIC PATIENTS TO PREDICT THE DEVELOPMENTE OF HCC

Angelo Sangiovanni, Eleonora Alimenti, Riccardo Gattai, Roberto Filomia, Elisabetta Parente, Luca Valenti, Luca Marzi, Giulia Pieri, Guglielmo Borgia, Martina Gambato, Natalia Terreni, Ilaria Serio, Luca Belli, Filippo Oliveri, Sergio Maimone, Maria Corinna Plaz Torres, Roberta D'Ambrosio, Massimo Iavarone, Laura Virginia Forzenigo, Francesco Paolo Russo, Mariagrazia Rumi, Michele Barone, Anna Ludovica Fracanzani, Giovanni Raimondo, Edoardo G. Giannini, Maurizia Brunetto, Erica Villa, Annalisa De Silvestri, Massimo Colombo, Pietro Lampertico

HEPATOLOGY (2022)

添加到收藏夹

Meeting Abstract Gastroenterology & Hepatology

INCIDENCE AND RISK FACTORS OF ESOPHAGOGASTRIC VARICES BLEEDING IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA TREATED WITH LENVATINIB

Massimo Iavarone, Eleonora Alimenti, Toshifumi Tada, Shigeo Shimose, Goki Suda, Caterina Solda, Fabio Piscaglia, Andrea Casadei Gardini, Fabio Marra, Caterina Vivaldi, Fabio Conti, Marta Schirippa, Hideki Iwamoto, Takuya Sho, Mario Domenico Rizzato, Matteo Tonnini, Margherita Rimini, Giulia Tosetti, Claudia Campani, Gianluca Masi, Francesco Giuseppe Foschi, Takumi Kawaguchi, Takashi Kumada, Atsushi Hiraoka, Masanori Atsukawa, Shinya Fukunishi, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Atsushi Naganuma, Pietro Lampertico

HEPATOLOGY (2022)

添加到收藏夹

Meeting Abstract Immunology

Impact of pre-liver transplant treatments on imaging accuracy of HCC staging and their influence on outcome

D. Dondossola, A. Schelgel, M. Iavarone, F. Donato, G. Marini, C. Guerci, A. Zefelippo, B. Antonelli, L. Caccamo, G. Rossi, P. Muiesan

TRANSPLANTATION (2022)

添加到收藏夹

Meeting Abstract Gastroenterology & Hepatology

Usefulness of longitudinal assessment of AFP in DAA cured HCV cirrhotic patients to predict the developmente of HCC

Angelo Sangiovanni, Eleonora Alimenti, Riccardo Gattai, Roberto Filomia, Elisabetta Parente, Luca Valenti, Luca Marzi, Giulia Pieri, Guglielmo Borgia, Martina Gambato, Natalia Terreni, Ilaria Serio, Luca Saverio Belli, Filippo Oliveri, Sergio Maimone, Maria Corinna Plaz Torres, Roberta D'Ambrosio, Massimo Iavarone, Laura Virginia Forzenigo, Francesco Paolo Russo, Maria Grazia Rumi, Michele Barone, Anna Ludovica Fracanzani, Giovanni Raimondo, Edoardo Giovanni Giannini, Maurizia Brunetto, Erica Villa, Annalisa De Silvestri, Massimo Colombo, Pietro Lampertico

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Meeting Abstract Gastroenterology & Hepatology

Humoral, cellular, clinical responses and safety to SARS-CoV-2 messanger RNA vaccines in patients with compensated and decompensated cirrhosis: a long-term single center prospective study

Massimo Iavarone, Giulia Tosetti, Floriana Facchetti, Matilde Topa, Andrea Lombardi, Roberta D'Ambrosio, Elisabetta Degasperi, Alessandro Loglio, Chiara Oggioni, Alessandra Bandera, Andrea Gori, Ferruccio Ceriotti, Luigia Scudeller, Antonio Bertoletti, Pietro Lampertico

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.